Cytosorbents (CTSO) Receivables - Other (2017 - 2026)

Cytosorbents has reported Receivables - Other for 10 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 17.71% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 17.71% YoY), and the FY2025 full-year result was $7.1 million, up 27.23% from the prior year.
• Receivables - Other for Q1 2026 stood at $6.9 million, down from $7.1 million in the prior quarter.
• The five-year high for Receivables - Other was $7.1 million in Q4 2025, with the low at $3.2 million in Q1 2022.
• Historically, Receivables - Other has averaged $5.2 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Other surged 38.65% — and 2024, when it increased 5.66%.
• Cytosorbents' Receivables - Other stood at $3.8 million in 2022, then surged by 38.65% to $5.3 million in 2023, then grew by 5.66% to $5.6 million in 2024, then climbed by 27.23% to $7.1 million in 2025, then declined by 3.16% to $6.9 million in 2026.
• The last three Receivables - Other figures came in at $6.9 million (Q1 2026), $7.1 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.